print
*trials of mRNA vaccines for infectious diseases were somewhat modest, leading to cautious expectations.
*blood coagulation and pathological thrombus.
* local and systemic inflammation.
*autoimmunity issues.
*edema
From a peer-reviewed journal article, published in January 2018, I scatter below for your edification a candid, matter-of-fact documentation of known reservation about the mRNA vaccines, intended for healthy individuals.
Clearly, “science” was freer as recently as 2018, in credible medical journals, and prior to the consolidation of a consensus around the SARS-CoV-2 vaccines, a consensus driven by the COVID cartel.
“…… extracellular RNA promoted blood coagulation and pathological thrombus formation… the paradoxical effects of innate immune sensing on different formats of mRNA vaccines are incompletely understood.
“… recently published results from two clinical trials of mRNA vaccines for infectious diseases were somewhat modest, leading to more cautious expectations about the translation of preclinical success to the clinic… .”
A possible concern could be that some mRNA-based vaccine platforms induce potent type I interferon responses, which have been associated not only with inflammation but also potentially with autoimmunity167,168. Thus, identification of individuals at an increased risk of autoimmune reactions before mRNA vaccination may allow reasonable precautions to be taken.
I think I distilled the main concerns. But do READ:
“mRNA vaccines — a new era in vaccinology,” Norbert Pardi, Michael J. Hogan, Frederick W. Porter & Drew Weissman, Nature Reviews Drug Discovery volume 17, pages261–279 (2018)